Inclusion Criteria:

- Male or female Chinese subjects >/- 18 years

- Advanced, histologically or cytologically confirmed solid tumors

- Subjects malignancies must be refractory to standard treatment or have no standard
therapy available, or the subject actively refused any treatment that would be
regarded standard, and/or if, in the judgment of the investigator or his/her
designated associate(s), experimental treatment is clinically and ethically
acceptable.

- Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-1;

- Adequate bone marrow, liver and renal function

- Life expectancy of at least 3 months

Exclusion Criteria:

- Unstable/uncontrolled cardiac disease

- History of arterial or venous thrombotic or embolic events

- Malabsorption condition

- Severe renal impairment; persistent proteinuria >/= Grade 3

- Symptomatic metastatic brain or meningeal tumors

- Clinically significant bleeding >/=Grade 3 within 30 days before start of study
medication.